EconPapers    
Economics at your fingertips  
 

Prognostic and predictive value of a pathomics signature in gastric cancer

Dexin Chen, Meiting Fu, Liangjie Chi, Liyan Lin, Jiaxin Cheng, Weisong Xue, Chenyan Long, Wei Jiang, Xiaoyu Dong, Jian Sui, Dajia Lin, Jianping Lu, Shuangmu Zhuo (), Side Liu (), Guoxin Li (), Gang Chen () and Jun Yan ()
Additional contact information
Dexin Chen: Southern Medical University
Meiting Fu: Southern Medical University
Liangjie Chi: Southern Medical University
Liyan Lin: Fujian Cancer Hospital
Jiaxin Cheng: Southern Medical University
Weisong Xue: Southern Medical University
Chenyan Long: Southern Medical University
Wei Jiang: Southern Medical University
Xiaoyu Dong: Southern Medical University
Jian Sui: Southern Medical University
Dajia Lin: Southern Medical University
Jianping Lu: Fujian Cancer Hospital
Shuangmu Zhuo: Jimei University
Side Liu: Southern Medical University
Guoxin Li: Southern Medical University
Gang Chen: Fujian Cancer Hospital
Jun Yan: Southern Medical University

Nature Communications, 2022, vol. 13, issue 1, 1-13

Abstract: Abstract The current tumour-node-metastasis (TNM) staging system alone cannot provide adequate information for prognosis and adjuvant chemotherapy benefits in patients with gastric cancer (GC). Pathomics, which is based on the development of digital pathology, is an emerging field that might improve clinical management. Herein, we propose a pathomics signature (PSGC) that is derived from multiple pathomics features of haematoxylin and eosin-stained slides. We find that the PSGC is an independent predictor of prognosis. A nomogram incorporating the PSGC and TNM staging system shows significantly improved accuracy in predicting the prognosis compared to the TNM staging system alone. Moreover, in stage II and III GC patients with a low PSGC (but not in those with a high PSGC), satisfactory chemotherapy benefits are observed. Therefore, the PSGC could serve as a prognostic predictor in patients with GC and might be a potential predictive indicator for decision-making regarding adjuvant chemotherapy.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-34703-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34703-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-34703-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34703-w